Menu
Search
|

Menu

Close
X

Evolus Inc EOLS.OQ (NASDAQ Stock Exchange Global Market)

11.73 USD
-0.36 (-2.98%)
As of 1:56 AM IST
chart
Previous Close 12.09
Open 12.08
Volume 30,918
3m Avg Volume --
Today’s High 12.14
Today’s Low 11.60
52 Week High 12.83
52 Week Low 9.68
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
EPS (USD)
FY17
-0.112
FY16
-0.335
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Vikram Malik
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Murthy Simhambhatla
President, Chief Executive Officer, Director, Since 2016
Salary: $500,000.00
Bonus: --
J. Christopher Marmo
Chief Operating Officer, Since 2016
Salary: $407,550.00
Bonus: --
Rui Avelar
Chief Medical Officer, Since 2014
Salary: $325,000.00
Bonus: --
Simone Blank
Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

17901 von Karman Ave Ste 150
IRVINE   CA   92614-5245

Phone: +1949.2844555

Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.

SPONSORED STORIES